HRSA 340B and GLP-1s: The Hospital Pricing Loophole

The 340B program offers deeply discounted GLP-1s through safety-net hospitals and FQHCs. Here's how the pricing actually works and who can access it.

The 340B Drug Pricing Program is one of the most consequential — and least publicly understood — drug pricing mechanisms in the United States. Administered by the Health Resources and Services Administration, 340B requires drug manufacturers to offer deep discounts on outpatient drugs to qualifying hospitals and clinics that serve low-income and vulnerable populations. For GLP-1s, 340B represents an access channel that sits outside commercial cash-pay, Medicare, and TrumpRx entirely.

Patients who receive care at a 340B-eligible facility may be able to access brand-name Wegovy, Ozempic, or Zepbound at prices that beat every retail and cash-pay channel. The catch is that the eligibility and access pathway are nothing like what most patients think of when they shop for a GLP-1.

How 340B Pricing Works

Under Section 340B of the Public Health Service Act, drug manufacturers that participate in Medicaid are required to offer a ceiling-price discount to 340B-covered entities. The ceiling price is calculated as the average manufacturer price minus the unit rebate amount, which is tied to the drug's Medicaid best price. In practice, the 340B price is substantially below the commercial list price — often 20-50% off, depending on the drug.

For GLP-1 medications, 340B pricing has been active since the products became available. What has changed over the last three years is the volume of GLP-1s dispensed through 340B channels, which has grown as weight-management indications have expanded and as cardiovascular and kidney indications have been added to the labels.

Who Qualifies as a Covered Entity

Patients receiving care at these covered entities, and receiving their prescriptions through the entity's in-house or contract pharmacy, can benefit from 340B pricing. The discount is transmitted through the pharmacy system rather than paid out to patients directly — what the patient sees is simply a lower cash price, or in many cases a lower copay under their insurance.

The Access Reality

340B is not a consumer-facing benefit program. Patients don't enroll in 340B; they receive care at a covered entity and fill prescriptions through that entity's pharmacy system. For most patients seeking GLP-1 treatment, this means the access pathway is to establish care with an FQHC, safety-net hospital, or qualifying clinic that has an established GLP-1 prescribing program.

Not every covered entity aggressively prescribes GLP-1s. The medications require clinician evaluation, labs, and ongoing monitoring — resource-intensive care that many safety-net providers manage conservatively. Patients in areas with strong FQHC coverage and active GLP-1 prescribing programs have the best access; patients in underserved areas or at facilities that don't prioritize weight-management care have harder access.

340B in the Context of Other Pricing Channels

The 340B price for Wegovy or Zepbound is typically lower than the NovoCare and LillyDirect cash-pay prices, lower than retail pharmacy cash-pay, and competitive with Medicare's negotiated price once the January 2027 effective date arrives. The difference is that 340B requires the clinical care relationship to be with a covered entity, which narrows the eligible population significantly.

For patients whose income and geography qualify them for FQHC or other covered entity care, 340B is often the most affordable path to brand-name GLP-1 access. For patients outside those care relationships, the cash-pay channels (NovoCare $349, LillyDirect $299-449) and authorized telehealth ($249 subscription) are the most accessible options.

Recent Policy Tensions

The 340B program has been the subject of ongoing policy disputes between manufacturers, covered entities, and HRSA. Several major manufacturers — including Novo Nordisk — have limited the number of contract pharmacies through which they will honor 340B pricing, citing concerns about duplicate discounts and program integrity. Those restrictions have been the subject of federal litigation and regulatory rulemaking.

For GLP-1 patients accessing care through covered entities, the practical impact of those disputes has been narrower fulfillment options and, in some cases, longer travel distances to access 340B pricing. The program remains in place and continues to serve millions of patients, but the operational footprint for specific drugs changes year over year. See our related reporting on Medicare's semaglutide negotiation and the TrumpRx federal portal for how 340B compares to other government-adjacent pricing channels.

Affiliate Disclosure: Some provider links on this page are affiliate links. If you sign up through these links, we may receive compensation at no additional cost to you. This does not influence our editorial content, pricing data, or provider selection.